Report of Foreign Issuer (6-k)
December 10 2018 - 1:57PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of
1934
For the month of December 2018
Commission File No.:001-35773
REDHILL BIOPHARMA LTD.
(Translation of registrant’s name
into English)
21 Ha'arba'a Street, Tel Aviv, 64739,
Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the Registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the Registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Attached hereto and incorporated by reference
herein are the following exhibits:
Exhibit 1.1
: Underwriting Agreement, dated
December 6, 2018, between the Registrant and Ladenburg Thalmann & Co. Inc. and Nomura Securities International Inc., as representative
of the several Underwriters
Exhibit 5.1
: Opinion of Gross, Kleinhendler,
Hodak, Halevy, Greenberg, Shenhav & Co.
Exhibit 5.2
: Opinion of Haynes and Boone,
LLP.
Exhibit 23.1
: Consent of Gross, Kleinhendler,
Hodak, Halevy, Greenberg, Shenhav & Co. (included in Exhibit 5.1).
Exhibit 23.2
: Consent of Haynes and Boone,
LLP (included in Exhibit 5.2).
This Form 6-K shall not constitute an offer
to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of the securities in
any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities
laws of any such jurisdiction.
This Form 6-K and related exhibits are
incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission
on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration
No. 333-219441) and on May 23, 2018 (Registration No. 333-225122) and its Registration Statements on Form F-3 filed with the Securities
and Exchange Commission on February 25, 2016 (Registration No. 333- 209702) and on July 23, 2018 (Registration No. 333-226278).
Signatures
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
|
REDHILL BIOPHARMA LTD
|
|
|
(Registrant)
|
|
|
|
|
|
|
Date: December 10, 2018
|
|
By:
/s/ Dror Ben-Asher
|
|
|
Dror Ben-Asher
|
|
|
Chief Executive Officer
|
Redhill Biopharma (NASDAQ:RDHL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Redhill Biopharma (NASDAQ:RDHL)
Historical Stock Chart
From Apr 2023 to Apr 2024